RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer